[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Santa Chiara Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100591511","prostate-cancer-plasma-integrative-multi-modal-evaluation-100591511",false,"NCT06981377","PRostate Cancer Plasma Integrative Multi-modal Evaluation","Development of the PRIME Test for the Identification of Prostate Cancer Patients' Biomarkers Through Non-invasive Liquid Biopsies","PRIME","Inclusion Criteria:\n\n* Diagnosis of prostate cancer\n* Eligible for prostate cancer pharmacological treatment\n* Given consent to study participation\n\nExclusion Criteria:\n\n\\- Histological diagnosis other than prostate cancer","MALE","18 Years",{"count":20,"type":21},800,"ESTIMATED","OBSERVATIONAL","The study aims to develop PRIME (PRostate cancer plasma Integrative Multi-modal Evaluation) liquid biopsy test and to implement its use to query prospectively collected samples in advanced prostate cancer (PCa) clinical trials and\u002For clinical settings. In order to maximise the utility of liquid biopsies for advanced PCa, PRIME is focused on the development of novel computational and sequencing approaches that integrate multiple information from plasma circulating elements: i) cell free DNA (cfDNA) gene mutation data with accurate quantitation of cfDNA structural genomic changes, ii) cfDNA genomic profiling with cfDNA methylation status, and iii) the information provided by extracellular vesicles (EVs) and EV-associated cargo (including DNA, RNA and proteins).",[25],"Metastatic Prostate Cancer",[27,28,29,30],"Liquid biopsy","Cell free DNA (cfDNA)","Extracellular Vesicles (EVs)","Biomarkers","RECRUITING","2025-05-13",{"date":34,"type":35},"2025-05-20","ACTUAL",{"date":37,"type":35},"2019-05-07",{"date":39,"type":21},"2027-01-31",{"name":41,"class":42},"Santa Chiara Hospital","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100576271","clinical-outcomes-of-use-of-olaparib-in-castration-resistant-prostate-cancer-100576271","NCT06783127","Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer","Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study","COROS","Inclusion Criteria:\n\nBRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice\n\nExclusion Criteria:\n\nOlaparib treatment in a clinical trial",{"count":53,"type":21},3000,"This is an observational, retrospective\u002Fprospective, multicenter study designed to define, overall survival, clinical outcomes and predictive\u002Fprognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.",[56,57,58],"Prostate Cancer","Castrate Resistant Prostate Cancer","BRCA Mutation","2025-02-07",{"date":61,"type":35},"2025-02-11",{"date":63,"type":35},"2023-01-01",{"date":65,"type":21},"2026-12-31",{"name":41,"class":42},2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":77,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":5},"100552451","evaluation-of-clinical-outcomes-of-chemotherapy-or-androgen-receptor-targeting-agent-alone-or-combined-or-radiotherapy-on-primary-tumor-in-addition-to-androgen-deprivation-therapy-in-hormone-sensitive-metastatic-prostate-cancer-patients-100552451","NCT06473259","Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients","Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals","ECHOS","Inclusion Criteria:\n\n1. histologically confirmed diagnosis of adenocarcinoma of the prostate, metastatic, not undergoing previous treatment (except hormone therapy initiated no more than 4-6 months prior to docetaxel) for metastatic disease\n2. treatment with docetaxel, ARPI (alone or in combination) or with radiation therapy on the primary tumor in combination with ADT within normal clinical practice or expanded access programs initiated between January 2015 and December 2027.\n3. availability of inpatient and\u002For outpatient medical records for clinical data collection\n\nExclusion Criteria:\n\n1. histological diagnosis other than adenocarcinoma\n2. patients who have received multiple lines of ADT for mCSPC\n3. patients who have received docetaxel or ARTA for metastatic castration-resistant disease",{"count":53,"type":21},"5 Years","The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice",[56,80,81],"Hormone Sensitive Prostate Cancer","Metastatic Tumor","2024-06-24",{"date":84,"type":35},"2024-06-25",{"date":86,"type":35},"2016-12-16",{"date":88,"type":21},"2028-12",{"name":41,"class":42},""]